Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), launched AAVelocityTM, a plug-and-play Adeno-Associated Virus (AAV) platform. AAVelocity is designed to bring cost and time-efficiencies to drug developers in the production of AAV gene delivery systems used to transport a gene therapy into tissue to prevent, treat or cure inherited disorders and rare diseases.
The AAVelocity plug-and-play platform can provide a 12-month turnaround on drug developer projects, lowering industry average standard bioprocessing timeframes by at least six months and helping clients save on associated costs.
Also new is AAVelocity’s inherent flexibility. This enables bioproduction teams to easily adapt to client requirements, such as achieving different purity levels within strict time constraints. It includes delivering AAVs containing the optimized amount of genetic material. AAVelocity's agility also avoids intermediary steps or the addition of others, while ensuring total integrity and purity of the genetic material.
The improved efficacy of AAVelocity will bring greater benefits to drug developers and their pipelines, according to SK pharmteco. Using single-use bioreactors, the AAV platform is scalable to meet any client need: 10L > 50L > 200L > 2 x 200L > 1000L.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!